We propose that combining an EGFR inhibitor and 5-Fu may be beneficial for advanced CRC, in line with recent clinical trials demonstrating that adding panitumumab, another anti-EGFR antibody, to standard first-line chemotherapy (mFOLFOX6) significantly improved overall survival in patients with unresectable, RAS wild-type, left-sided, metastatic CRC, compared to adding an anti-VEGF antibody (bevacizumab) to mFOLFOX6 [23]. The gene discussed is VEGFA; the disease is colorectal carcinoma.